Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst

On Tuesday, Eli Lilly And Co (NYSE:LLY) agreed to acquire Verve Therapeutics, Inc. (NASDAQ:VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease. Lilly offered to purchase Verve for $10.50 per share in cash, an aggregate of approximately $1.0 billion,…